Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.

Neurology

From the Clinical Memory Research Unit (C.C., N.M.-C., S.P., K.A., O.S., E.S., S.J., O.H.), Department of Clinical Sciences, Lund University; Memory Clinic (C.C., S.P., E.S., O.H.), Skåne University Hospital, Malmö; Department of Neurology (N.M.-C.), Skåne University Hospital, Wallenberg Center for Molecular Medicine (N.M.-C.), and Department of Clinical Sciences Lund (D.v.W.), Diagnostic Radiology, Lund University; Imaging and Function (D.v.W.), Skåne University Health Care, Lund; Department of Psychiatry and Neurochemistry (H.Z., K.B.), the Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Clear Water Bay, China; and Department of Neuropsychology (K.A.), Ruhr University Bochum, Germany.

Published: July 2023

Background And Objectives: Injured pericytes in the neurovascular unit release platelet-derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury contributes to Alzheimer disease (AD)-related changes and blood-brain barrier (BBB) damage. We aimed to test whether CSF PDGFRβ was associated with different AD-associated and age-associated pathologic changes leading to dementia.

Methods: PDGFRβ was measured in the CSF of 771 participants with cognitively unimpaired (CU, n = 408), mild cognitive impairment (MCI, n = 175), and dementia (n = 188) from the Swedish BioFINDER-2 cohort. We then checked association with β-amyloid (Aβ)-PET and tau-PET standardized uptake value ratio, ε4 genotype and MRI measurements of cortical thickness, white matter lesions (WMLs), and cerebral blood flow. We also analyzed the role of CSF PDGFRβ in the relationship between aging, BBB dysfunction (measured by CSF/plasma albumin ratio, QAlb), and neuroinflammation (i.e., CSF levels of YKL-40 and glial fibrillary acidic protein [GFAP], preferentially expressed in reactive astrocytes).

Results: The cohort had a mean age of 67 years (CU = 62.8, MCI = 69.9, dementia = 70.4), and 50.1% were male (CU = 46.6%, MCI = 53.7%, dementia = 54.3%). Higher CSF PDGFRβ concentrations were related to higher age ( = 19.1, β = 0.5, 95% CI 16-22.2, < 0.001), increased CSF neuroinflammatory markers of glial activation YKL-40 ( = 3.4, β = 0.5, 95% CI 2.8-3.9, < 0.001), GFAP ( = 27.4, β = 0.4, 95% CI 20.9-33.9, < 0.001), and worse BBB integrity measured by QAlb ( = 37.4, β = 0.2, 95% CI 24.9-49.9, < 0.001). Age was also associated with worse BBB integrity, and this was partly mediated by PDGFRβ and neuroinflammatory markers (16%-33% of total effect). However, PDGFRβ showed no associations with ε4 genotype, PET imaging of Aβ and tau pathology, or MRI measures of brain atrophy and WMLs ( > 0.05).

Discussion: In summary, pericyte damage, reflected by CSF PDGFRβ, may be involved in age-related BBB disruption together with neuroinflammation, but is not related to Alzheimer-related pathologic changes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351311PMC
http://dx.doi.org/10.1212/WNL.0000000000207358DOI Listing

Publication Analysis

Top Keywords

csf pdgfrβ
20
pathologic changes
12
pdgfrβ
9
blood-brain barrier
8
alzheimer disease
8
csf
8
ε4 genotype
8
neuroinflammatory markers
8
worse bbb
8
bbb integrity
8

Similar Publications

Objectives The optimal dosing schedule strategy for granulocyte colony-stimulating factor (G-CSF) in healthy stem cell donors remains controversial. This study aimed to compare the efficacy of once-daily versus twice-daily G-CSF administration in allogeneic stem cell donors. Materials and methods We retrospectively analyzed data from 388 healthy unrelated donors (282 males, 106 females) who underwent stem cell mobilization at our center between September 2018 and June 2022.

View Article and Find Full Text PDF

A 65-year-old woman with Multiple Sclerosis treated with fingolimod developed headaches and convulsions. Cerebrospinal fluid (CSF) culture indicated . A literature review of 20 cases of cryptococcal meningitis indicated that headache was the most common initial symptom, and all cases were positive for serum and/or CSF cryptococcal antigens.

View Article and Find Full Text PDF

Background: Although Amyloid-beta and Tau are the hallmarks of Alzheimer's Disease (AD), other protein pathways such as endothelial dysfunction may be involved and may precede cognitive symptoms. Our objective was to characterize the cerebrospinal fluid (CSF) proteomic profiles focusing on cardiometabolic-related protein pathways in individuals on the AD spectrum.

Methods: We performed CSF and plasma-targeted proteomics (276 proteins) from 354 participants of the Brain Stress Hypertension and Aging Program (BSHARP), of which 8% had preclinical AD, and 24% had MCI due to AD.

View Article and Find Full Text PDF

Background: Recent studies have shown that cerebrospinal fluid (CSF) levels of soluble triggering receptor expressed on myeloid cells 1 (sTREM1) are elevated in individuals with Alzheimer's disease (AD), though the relationship between CSF sTREM1 and hippocampal atrophy remains to be elucidated. The primary aim of this study was to investigate the association between CSF sTREM1 levels and longitudinal changes in hippocampal volumes, and to determine if this relationship is moderated by cognitive status.

Methods: We included 576 participants, comprising 152 cognitively unimpaired (CU) and 424 cognitively impaired (CI) individuals.

View Article and Find Full Text PDF

Introduction: This study aimed to assess the impact of prophylactic use of PEG-rhG-CSF on first-line immunochemotherapy in advanced NSCLC.

Methods: A cohort of patients with advanced NSCLC who received first-line immunochemotherapy at Shengjing Hospital of China Medical University between January 2019 and July 2024 was selected for this study. Patients were divided into the following two groups: a treatment group that received prophylactic PEG-rhG-CSF (≥1 cycle) 48 hours after immunochemotherapy and a control group that did not receive PEG-rhG-CSF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!